DiaSorin stock at EUR 78.06, 7.8 percent below consensus target

Published on 10/12/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 revenue was EUR 602 million, flat at constant rates. DiaSorin stock costs EUR 78.06 on October 12, 2026 versus a EUR 79.72 high.

Key points in brief

DiaSorin stock was at EUR 78.06 at Lang & Schwarz on October 12, 2026 at 1:14 p.m. CEST.
The price is 7.80 percent below the EUR 84.15 median analyst target cited for 18 analysts.
First-half 2026 revenue was EUR 602 million, flat at constant exchange rates, while adjusted EBITDA was EUR 194 million.
The finance calendar lists November 5, 2026 for the third-quarter 2026 earnings release.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin stock (ISIN IT0003492391) was at EUR 78.06 at Lang & Schwarz on October 12, 2026 at 1:14 p.m. CEST. The price stood 7.80 percent below the EUR 84.15 median analyst target listed by Eulerpool for 18 analysts.

Price sits near yearly high

The current euro price is EUR 1.66 below DiaSorin's 52-week high of EUR 79.72 and EUR 25.72 above its 52-week low of EUR 52.34, based on the October 12, 2026 quote. That places the stock close to the upper end of its annual range while the valuation remains visible in the market data.

Market capitalization stood at EUR 3.9 billion on October 12, 2026, with a price-to-earnings ratio of 24.33 and a trailing dividend yield of 0.02 percent. The valuation picture is therefore defined by a mid-20s earnings multiple rather than by a high cash yield.

First-half figures frame valuation

Yahoo Finance reported on July 31, 2026 that first-half 2026 revenue reached EUR 602 million, flat at constant exchange rates, while second-quarter revenue grew 4 percent at constant exchange rates. Adjusted EBITDA for the first half was EUR 194 million, down 7 percent at constant exchange rates, with an adjusted EBITDA margin of 32 percent.

Management confirmed full-year 2026 guidance for revenue growth of 5 percent to 6 percent and an adjusted EBITDA margin of 32 percent to 33 percent in the same earnings call. The contrast between flat first-half revenue and the full-year growth range makes second-half execution the central numerical test for the valuation.

Comparison with peers

DiaSorin: no daily change, P/E 24.33, market capitalization EUR 3.9 billion

Roche (SIX, CHF):

bioMerieux (Euronext Paris, EUR):

Next earnings date is November 5

The next scheduled reporting date is November 5, 2026, when DiaSorin is expected to report third-quarter results, according to Yahoo Finance. That release should provide the next quantified update on revenue growth, margin delivery and the rollout of newer diagnostic platforms.

DiaSorin stock remains near its high

At EUR 78.06, the stock was EUR 1.66 below its 52-week high and 7.80 percent below the EUR 84.15 median analyst target on October 12, 2026. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.